TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
23 hedge funds and large institutions have $41.9M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 6 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
5% less capital invested
Capital invested by funds: $44M → $41.9M (-$2.11M)
15% less funds holding
Funds holding: 27 → 23 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.14M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$446K |
| 3 |
WG
Welch Group
Birmingham,
Alabama
|
+$260K |
| 4 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$134K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$1.66M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$262K |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$84K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$66K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Janus Henderson Group
London,
United Kingdom
| – | -$63K | -32 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$13K | -7 | Closed |
|
28
Morgan Stanley
New York
| – | -$3K | -1 | Closed |
|
|
PCM
29
Prelude Capital Management
New York
| – | -$2K | -1 | Closed |
|
TCON Hedge Fund Activity: Q4 2015 in Review
23 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2015, worth a combined $41.9M — down 4.8% from $44M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TCON and 2 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 11 added.
The largest buyer was Eventide Asset Management, adding an estimated $1.14M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $1.66M sold.
- 23 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2015, down from 27 in Q3 2015.
- Funds reported $41.9M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2015, down 4.8% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2015 and 6 closed out, a net change of -4 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2015 was Eventide Asset Management, an estimated $1.14M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2015 was J. Goldman & Co, an estimated $1.66M sold.
Based on aggregated 13F filings for Q4 2015.